Growth Factor‐Mediated Stabilization of Amyloid Precursor Protein mRNA Is Mediated by a Conserved 29‐Nucleotide Sequence in the 3′‐Untranslated Region

Abstract: Using a cell‐free translation system, we previously demonstrated that the turnover and translation of amyloid precursor protein (APP) mRNA was regulated by a 29‐nucleotide instability element, located 200 nucleotides downstream from the stop codon. Here we have examined the regulatory role of this element in primary human capillary endothelial cells under different nutritional conditions. Optimal proliferation required a growth medium (endothelial cell growth medium) supplemented with epidermal, basic fibroblast, insulin‐like, and vascular endothelial growth factors. In vitro transcribed mRNAs with the 5′‐untranslated region (UTR) and coding region of β‐globin and the entire 3′‐UTR of APP 751 were transfected into cells cultured in endothelial cell growth medium. Wild‐type globin‐APP mRNA containing an intact APP 3′‐UTR and mutant globin‐APP mRNA containing a mutated 29‐nucleotide element decayed with identical half‐lives (t1/2 = 60 min). Removal of all supplemental growth factors from the culture medium significantly accelerated the decay of transfected wild‐type mRNA (t1/2 = 10 min), but caused only a moderate decrease in the half‐life of transfected mutant mRNA (t1/2 = 40 min). We therefore conclude that the 29‐nucleotide 3′‐UTR element is an mRNA destabilizer whose function can be inhibited by inclusion of the aforementioned mixture of growth factors in the culture medium.

[1]  C. Cahill,et al.  Translation of the Alzheimer Amyloid Precursor Protein mRNA Is Up-regulated by Interleukin-1 through 5′-Untranslated Region Sequences* , 1999, The Journal of Biological Chemistry.

[2]  P. Reiner,et al.  Regulation of Amyloid Precursor Protein Cleavage , 1999, Journal of neurochemistry.

[3]  J. LaManna,et al.  Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. , 1998, Brain research. Molecular brain research.

[4]  C. Moroni,et al.  c‐jun N‐terminal kinase is involved in AUUUA‐mediated interleukin‐3 mRNA turnover in mast cells , 1998, The EMBO journal.

[5]  A. Placzek,et al.  Alzheimer's β-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40 , 1998, Brain Research.

[6]  G. Brewer,et al.  Upregulation of amyloid precursor protein gene promoter in rat primary hippocampal neurons by phorbol ester, IL-1 and retinoic acid, but not by reactive oxygen species. , 1998, Brain research. Molecular brain research.

[7]  J. Malter,et al.  hnRNP C increases amyloid precursor protein (APP) production by stabilizing APP mRNA. , 1998, Nucleic acids research.

[8]  M. Karin,et al.  Stabilization of interleukin-2 mRNA by the c-Jun NH2-terminal kinase pathway. , 1998, Science.

[9]  Douglas R. McDonald,et al.  β-Amyloid Fibrils Activate Parallel Mitogen-Activated Protein Kinase Pathways in Microglia and THP1 Monocytes , 1998, The Journal of Neuroscience.

[10]  L. Mucke,et al.  Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease , 1997, Nature.

[11]  P. Gluckman,et al.  Insulin-like growth factor-I (IGF-I) immunoreactivity in the Alzheimer's disease temporal cortex and hippocampus. , 1997, Brain research. Molecular brain research.

[12]  S. Murray,et al.  Transcriptional and post‐transcriptional control of lysyl oxidase expression in vascular smooth muscle cells: Effects of TGF‐β1 and serum deprivation , 1997, Journal of cellular biochemistry.

[13]  R. Oliva,et al.  Conserved elements in the 5′ regulatory region of the amyloid precursor protein gene in primates , 1997, Neuroscience Letters.

[14]  S. Aschmies,et al.  ADDITIVE EFFECTS OF BASIC FIBROBLAST GROWTH FACTOR AND PHORBOL ESTER ON β-AMYLOID PRECURSOR PROTEIN EXPRESSION AND SECRETION , 1997, Neurochemistry International.

[15]  N. Perrone-Bizzozero,et al.  The Elav-like Proteins Bind to a Conserved Regulatory Element in the 3′-Untranslated Region of GAP-43 mRNA* , 1997, The Journal of Biological Chemistry.

[16]  L. Mucke,et al.  Cellular signaling roles of TGFβ, TNFα and βAPP in brain injury responses and Alzheimer's disease , 1997, Brain Research Reviews.

[17]  B. Winblad,et al.  Quantification of APP and APLP2 mRNA in APOE genotyped Alzheimer's disease brains. , 1996, Brain research. Molecular brain research.

[18]  R. Beavis,et al.  The length of Amyloid-β in Hereditary Cerebral Hemorrhage with Amyloidosis, Dutch Type , 1996, The Journal of Biological Chemistry.

[19]  J. Malter,et al.  Turnover and Translation of in Vitro Synthesized Messenger RNAs in Transfected, Normal Cells* , 1996, The Journal of Biological Chemistry.

[20]  J. Sussenbach,et al.  Growth-condition-dependent regulation of insulin-like growth factor II mRNA stability. , 1996, The Biochemical journal.

[21]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[22]  K. Urakami,et al.  Analysis of amyloid precursor protein mRNAs in skin fibroblasts in Down's syndrome. , 1996, Dementia.

[23]  D. Premkumar,et al.  Altered Expression of Amyloid β Precursor mRNAs in Cerebral Vessels, Meninges, and Choroid Plexus in Alzheimer's Disease a , 1996, Annals of the New York Academy of Sciences.

[24]  S. Ng,et al.  Aberrant GAP-43 gene expression in Alzheimer's disease. , 1995, The American journal of pathology.

[25]  D. Graham,et al.  Apolipoprotein E ε4 allele is associated with deposition of amyloid β-protein following head injury , 1995, Nature Medicine.

[26]  J. Malter,et al.  Amyloid precursor protein mRNA stability is controlled by a 29-base element in the 3'-untranslated region. , 1994, The Journal of biological chemistry.

[27]  J. Malter,et al.  Modulation of granulocyte-macrophage colony-stimulating factor mRNA stability in vitro by the adenosine-uridine binding factor. , 1994, The Journal of biological chemistry.

[28]  D. Selkoe,et al.  Secreted beta-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Selkoe Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease , 1993, Trends in Neurosciences.

[30]  Yaakov Stern,et al.  Genetic susceptibility and head injury as risk factors for Alzheimer's disease among community‐dwelling elderly persons and their first‐degree relatives , 1993, Annals of neurology.

[31]  D. Selkoe,et al.  Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.

[32]  K. Yoshikawa,et al.  Degeneration in vitro of post-mitotic neurons overexpressing the Alzheimer amyloid protein precursor , 1992, Nature.

[33]  D. Selkoe,et al.  Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments , 1992, Nature.

[34]  D. Holtzman,et al.  Dysregulation of gene expression in mouse trisomy 16, an animal model of Down syndrome. , 1992, The EMBO journal.

[35]  S. Deeb,et al.  Overexpression of amyloid precursor protein alters its normal processing and is associated with neurotoxicity. , 1992, Biochemical and biophysical research communications.

[36]  Y. Nagamine,et al.  Protein synthesis inhibition stabilizes urokinase-type plasminogen activator mRNA. Studies in vivo and in cell-free decay reactions. , 1991, The Journal of biological chemistry.

[37]  N. Sato,et al.  Cytokine messenger RNA stability is enhanced in tumor cells. , 1991, Blood.

[38]  R. Wisdom,et al.  The protein-coding region of c-myc mRNA contains a sequence that specifies rapid mRNA turnover and induction by protein synthesis inhibitors. , 1991, Genes & development.

[39]  M. Goldberg,et al.  Erythropoietin mRNA levels are governed by both the rate of gene transcription and posttranscriptional events. , 1991, Blood.

[40]  E. Stopa,et al.  Basic fibroblast growth factor in Alzheimer's disease. , 1990, Biochemical and biophysical research communications.

[41]  C. Finch,et al.  Relation of neuronal APP-751/APP-695 mRNA ratio and neuritic plaque density in Alzheimer's disease. , 1990, Science.

[42]  K. Beyreuther,et al.  Transgenic mice and Alzheimer's disease , 1990, Neurobiology of Aging.

[43]  H. W. Harris,et al.  Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[44]  W. Griffin,et al.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Ross,et al.  Regulation of c-myc mRNA stability in vitro by a labile destabilizer with an essential nucleic acid component , 1989, Molecular and cellular biology.

[46]  G. Sonenshein,et al.  Serum deprivation of vascular smooth muscle cells enhances collagen gene expression. , 1988, The Journal of biological chemistry.

[47]  R. Beavis,et al.  The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease. , 1996, The Journal of biological chemistry.

[48]  C. Cotman,et al.  Transforming growth factor-β1 is in plaques in Alzheimer and Down pathologies , 1993 .

[49]  D. Selkoe,et al.  Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. , 1993, Trends in neurosciences.

[50]  C. Cotman,et al.  Transforming growth factor-beta 1 is in plaques in Alzheimer and Down pathologies. , 1993, Neuroreport.

[51]  D. Selkoe,et al.  Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. , 1992, Nature.

[52]  M. Greenberg,et al.  The c-fos transcript is targeted for rapid decay by two distinct mRNA degradation pathways. , 1989, Genes & development.